IGC Pharma (IGC) announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation in Alzheimer’s ...
IGC Pharma (IGC) announced additional interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback